HRSA Set an August 24 Deadline on 340B Rebates. Your Plan Is Already Paying for a Program It Can't See in Its Claims Data.

On July 31, HRSA announced a revised 340B Rebate Model Pilot Program, giving drug manufacturers until August 24 to submit rebate plans that take effect January 1, 2027. Almost every headline about it framed the story as a fight between manufacturers and hospitals. That framing misses who has been quietly funding the argument. Self-funded employers are already paying for 340B, IQVIA estimated the program added roughly $6.6 billion in cost to employer-sponsored plans in a single year, and the reason almost no benefits leader has ever raised it in a renewal meeting is simple: there is no field on a claim that says "340B." The pilot matters to employers not because it lowers anyone's cost next year, but because it forces the industry to build, for the first time, the claim-level identification plumbing that makes this spend measurable at all.

The Program You Fund but Never Contracted For

340B is a federal program that requires manufacturers to sell covered outpatient drugs at deep statutory discounts to qualifying safety-net providers, disproportionate share hospitals, community health centers, Ryan White clinics, and others. The stated purpose is to let those providers stretch scarce resources. Nothing in the statute requires the provider to pass the discount to the patient or the payer. The provider buys low and bills the payer at its ordinary contracted rate. The difference is program margin, and it is legal by design.

That design is fine in isolation. What has changed is scale. HRSA's own figures put 340B purchases at $53.7 billion in 2022 and above $100 billion in 2025. A program built around a narrow set of safety-net institutions now runs through a sprawling network of hospital-affiliated outpatient clinics and tens of thousands of contract pharmacies, many of them owned by the same large chains and PBM parent companies your plan already contracts with. When a program that size operates on the spread between acquisition cost and billed price, commercial payers become the funding source whether or not they ever agreed to be.

Why This Never Surfaces in a Benefits Review

Three structural blind spots keep 340B out of employer conversations.

First, the claim looks completely normal. A 340B-dispensed prescription carries no marker visible to the plan sponsor. Your PBM sees a fill at a network pharmacy. Your reporting sees a drug, a quantity, and an ingredient cost. There is no line item labeled "acquired at 60% below WAC."

Second, the money moves in two directions at once, on different clocks. Manufacturers are not obligated to pay a commercial rebate on a unit that was already sold at a 340B price, that would be a duplicate discount, which the statute prohibits. So when a manufacturer later identifies a claim as 340B, it can reverse the rebate. Your plan paid something close to list price on the front end and then loses the rebate on the back end, often two or three quarters later, arriving in your reporting as a vague "prior period adjustment."

Third, the largest dollars often sit outside the pharmacy benefit entirely. Physician-administered infusions billed through the medical benefit at a 340B hospital outpatient department are the highest-margin 340B transactions in the system, and they land in a claims file most pharmacy consultants never open.

Think of a general contractor who buys lumber at a trade account and invoices the homeowner at retail. The homeowner isn't being defrauded, that's the deal she signed. But she cannot manage what she can't itemize, and she certainly can't negotiate it at renewal if the invoice only ever shows one number.

Five Places 340B Shows Up in a Self-Funded Plan's Costs

1. Contract pharmacy dispensing at full commercial rates. When a member fills a specialty prescription at a pharmacy operating as a 340B contract pharmacy for a covered entity, the drug may have been acquired at a fraction of WAC while your plan pays its normal contracted rate. The spread is retained upstream. IQVIA's analysis of state employee plans found a weighted-average spread of about $139 per affected patient, ranging from roughly $23 in one state to $517 in another, a reminder that geographic footprint drives exposure far more than plan design does.

2. Rebate reversals and prior-period adjustments. This is the quiet one. Consider an illustrative case: a member on adalimumab fills at a 340B contract pharmacy. Reference-brand Humira carries a list price near $7,000 per month, with employer net cost after rebate reported closer to $2,800; several biosimilars list near $550. If the manufacturer later flags that claim as 340B and reverses the rebate, the plan's realized cost on that fill moves from roughly $2,800 toward $7,000, for a molecule available at a fraction of either figure. That single reversal is worth more than most plans recover from an entire year of formulary tinkering.

3. Site-of-care economics on infusions. Oncology biologics, infliximab, and other buy-and-bill products delivered in a 340B hospital outpatient department generate the widest acquisition-to-reimbursement gap in the system. Employers who have moved infusions to home or freestanding ambulatory settings have captured savings that had nothing to do with the drug and everything to do with where it was purchased.

4. Formulary and prescribing gravity toward higher-list-price brands. Program margin scales with list price. A covered entity earns more spread dispensing a $7,000 reference brand than a $550 biosimilar. That does not imply bad faith by any individual prescriber, but it does mean the financial current runs against biosimilar adoption in exactly the settings where your highest-cost members receive care.

5. Distorted trend. Because reversals land retroactively, they inflate current-year pharmacy trend with prior-year activity. If your renewal conversation is anchored to a trend number that silently contains last year's clawbacks, you are negotiating against a distorted baseline.

What the Pilot Actually Changes and What It Doesn't

Be precise here, because the industry commentary is already overselling it. The pilot is voluntary, limited to manufacturers of drugs selected under Medicare's Drug Price Negotiation Program for 2026 and 2027 applicability years, and it governs how covered entities receive the 340B price, upfront discount versus retrospective rebate. Employers get no direct data access and no direct savings from it.

What it does is establish claim-level verification as an operating norm. To pay a rebate, a manufacturer must validate a specific claim as 340B-eligible. Once that identification infrastructure exists for a narrow drug list, extending it is an operational question rather than a technological one. Duplicate-discount disputes that today get settled through retroactive estimates and blunt reversals become traceable to individual transactions. For plan sponsors, that is the precondition for ever auditing this category. It is worth watching for the same reason the first mandatory fee disclosures in retirement plans mattered: the number becomes arguable only after it becomes visible.

Meanwhile, the underlying access fight remains unsettled. Several states have enacted laws requiring manufacturers to honor 340B pricing for contract pharmacies; federal courts have split on whether those laws survive, and the question is widely expected to reach the Supreme Court. Employers with concentrated populations in states on either side of that split will see different economics for the same drug.

Questions Worth Putting in Writing

Ask your PBM: How do you identify 340B claims in our data, and can you produce a count and dollar total for the last twelve months? What is your contractual obligation when a manufacturer reverses a rebate on one of our claims, do you absorb it, pass it through, or offset it against a future guarantee? Are 340B-flagged claims excluded from our rebate guarantee, and where does that exclusion appear in the contract?

Ask your broker or consultant: What share of our specialty spend runs through pharmacies affiliated with 340B covered entities, and what share of our infusion spend is delivered in hospital outpatient departments? Have you modeled site-of-care redirection separately from formulary savings?

Ask your stop-loss carrier and your medical TPA: Are large infusion claims priced off a percent-of-charge arrangement at facilities that acquire those drugs at 340B pricing?

Where to Start This Month

Pull twelve months of prior-period rebate adjustments and ask your PBM to attribute them by cause. Run your top twenty specialty claimants against dispensing pharmacy NPI and facility, then cross-check against HRSA's public 340B OPAIS database of covered entities and contract pharmacies, it is free, searchable, and almost never used by plan sponsors. Separate your infusion spend by place of service. Then look at your PBM contract's definition of "rebate-eligible claim" and its treatment of retroactive adjustments; in most standard agreements the plan bears that risk entirely, and that allocation is negotiable.

Key Takeaways

340B is not a hospital-versus-manufacturer story that happens near your plan. It is a pricing structure your plan funds, priced into claims you cannot currently identify, with a back-end rebate reversal mechanism most contracts leave squarely on the employer. The August 24 rebate-plan deadline and the January 1, 2027 effective date will not change your costs next year. They will change what is knowable. Plans that build the measurement capability now, dispensing-site attribution, place-of-service segmentation, and contract language that caps retroactive adjustment exposure, will be the ones positioned to act when the data finally exists. The rest will keep reading it as a trend.